الفهرس 
A Prospective study of I.V. Vinflunine in the treatment of patients with advanced or metastatic urothelial carcinoma after failure of a platinum-containiing regimen and biomarker correlatesregimen and biomarker correlatesregimen and biomarker correlates regimen and biomarker correlates
AbstractOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
e is the only cytotoxic agent that had been tested as a second
line therapy in platinum refractory urothelial carcinoma patients in a phase III
clinical trial. The aim of our study was to evaluate the efficacy and safety of
vinflunine as a second line after failure of platinum containing regimen.
Patients and methods:
We prospectively included 27 patients of locally advanced or metastatic
urothelial cancer who presented to the National Cancer Institute (NCI) of Egypt.
The primary objective was to assess the disease control rate. However, the
secondary objectives were to assess the progression free survival (PFS) and
overall survival (OS).
Results:
A total of 27 patients were treated at the NCI of Egypt. Median age was
64.1 years (42.3-76.8). Male to female ratio was 26:1. Eastern Cooperative
Oncology group performance status was zero in 2 patients, one in 23 patients
while the ECOG PS 2 was in only 2 patients. The vast majority of the patients
received 2 cycles (12 patients), one patient received 3 cycles, 5 patients received
4 cycles, and 8 patients received 6 cycles while one patient received 8 cycles. A
complete response was observed in one patient, partial response in 9 patients
and stable disease in 12 patients and progressive disease in 5 patients with a
disease control rate of 81.4%. Median progression free survival (PFS) and
overall survival for the entire population were 3.45 months and 3.22 months
respectively. Median OS for the responders was 7.24 months. Toxicity was
mild, and grade 3-4 adverse events were anemia (11.1%), neutropenic fever
(4%), fatigue (14.8%) and constipation (7.4%)